Articles tagged "Monitoring"

2022 American Transplant Congress
Clinical Stratification of Pediatric Liver Transplant Recipients 4-5 Years Post-Transplant: 1^St Step Towards Personalized Management
W. Dixon¹, E. R. Perito¹, M. Tavakol¹, J. Bucuvalas², S. Feng¹
¹University of California, San Francisco, San Francisco, CA, ²Mount Sinai Kravis Children's Hospital and Recanati/Miller Transplantation Institute, Mount Sinai Health System, New York, NY
*Purpose: Recent surveillance biopsy studies strongly associate high normal ALT (>35U/L) with inflammatory histopathology and low normal ALT (15yrs (n=13; p=0.0006), chronic rejection (CR) diagnosis…
2022 American Transplant Congress
A Novel, High Throughput Droplet Digital PCR-Based Indel Quantification Method for the Detection of Circulating Donor-Derived Cell-Free DNA After Kidney Transplantation
J. G. Verhoeven¹, K. Boer¹, A. M. Peeters¹, M. C. Clahsen-van Groningen², J. I. Roodnat¹, J. van de Wetering¹, D. Nieboer³, D. A. Bost⁴, C. C. Baan¹, D. A. Hesselink¹
¹Department of Internal Medicine, Erasmus MC Transplant Institute, Rotterdam, Netherlands, ²Department of Pathology, University Medical Center Rotterdam, Rotterdam, Netherlands, ³Department of Public Health, University Medical Center Rotterdam, Rotterdam, Netherlands, ⁴JETA Molecular, Utrecht, Netherlands
*Purpose: Donor-derived cell-free DNA (ddcfDNA) is a promising minimally invasive biomarker for acute rejection (AR) in kidney transplant recipients. To assess the diagnostic value of…
2022 American Transplant Congress
Single-Cell CyTOF Profiling of Pediatric Immune Responses to Organ Transplantation Reveals a Novel Subpopulation of T Cells Significantly Correlating with Graft Health
M. Rao¹, M. Amouzgar¹, J. T. Harden¹, M. Lapasaran¹, A. Trickey¹, B. Armstrong², J. Odim³, T. Debnam³, C. Esquivel¹, S. C. Bendall¹, O. Martinez¹, S. M. Krams¹
¹Stanford University, Palo Alto, CA, ²Rho, Durham, NC, ³National Institutes of Health, Bethesda, MD
*Purpose: Solid organ transplant is lifesaving for children with end-stage heart, liver, or kidney disease. Protection of the transplanted organ from rejection requires long-standing immunosuppression.…
2022 American Transplant Congress
Removing DSA and Region from Organ Allocation
R. R. Goff¹, A. R. Wilk¹, J. Foutz¹, A. Robinson¹, S. E. Booker¹, K. Bradbrook¹, T. Mupfudze¹, N. Turgeon², M. Cooper³, D. Klassen¹
¹United Network for Organ Sharing, Richmond, VA, ²University of Texas at Austin, Austin, TX, ³Medstar Georgetown, Washington , D.C., DC
*Purpose: Over the past 4 years, the OPTN has removed Donation Service Area (DSA) and OPTN Region from deceased donor organ allocation with the goal…
2022 American Transplant Congress
Urine-based Assay For Detection Of Acute Rejection In Pediatric Kidney Transplant Recipients
C. Crane¹, K. Zeeb², E. Phebus², C. Benavides², W. Wong³, E. Ingulli²
¹UCSD/Rady Children's Hospital, San Diego, CA, ²UCSD Rady Children's Hospital, San Diego, CA, ³Massachusetts General Brigham, Boston, MA
*Purpose: Biomarkers such as donor-derived cell free DNA (cfDNA) and gene expression profiling are utilized in adult transplant patients (pts), but these tests lack sensitivity…
2022 American Transplant Congress
Absolute Quantification of Donor-Derived Cell-Free DNA Does Not Provide Additional Discriminating Power Over Donor-derived Cell-Free DNA Fraction for Detection of Allograft Rejection
R. Gohh¹, S. Jordan², R. N. Woodward³, K. M. Clark-Langone³, J. Morlan³, B. Silva³, M. Weir⁴
¹Alpert School of Medicine Brown University, Providence, RI, ²Cedars Sinai Medical Ctr, Los Angeles, CA, ³CareDx, Redwood City, CA, ⁴University of Maryland School of Medicine, Baltimore, MD
*Purpose: High level of background cell-free DNA (cfDNA) has been hypothesized as a concern for false negative results in molecular diagnostics for allograft rejection that…
2022 American Transplant Congress
Longitudinal Analysis of Donor-Derived Cell-Free DNA (dd-cfDNA) in En-Bloc Kidney Transplantation
S. K. Akkina¹, J. Klein², A. Khalil³, G. Shekhtman⁴, S. Patel⁴, N. Agrawal⁴, M. Fei⁴, N. Singh⁵, A. Desai¹
¹Loyola University Medical Center, Maywood, IL, ²University of Kansas Medical Center, Kansas City, KS, ³Dallas Nephrology Associates, Dallas, TX, ⁴CareDx, Brisbane, CA, ⁵Willis Knighton Health System, Shreveport, LA
*Purpose: The longitudinal dd-cfDNA patterns in en-bloc kidney transplant recipients have not been studied. It is unknown how the initial smaller mass of the two…
2022 American Transplant Congress
Therapeutic Drug Monitoring of Crushed Posaconazole Delayed Release Tablets in Lung Transplant Patients
S. Sial, K. Cunningham, J. Moore, C. Dagostino, K. Lang, C. Kane
Northwestern Memorial Hospital, Chicago, IL
*Purpose: Lung transplant patients are at an increased risk for invasive fungal infections and often require prophylaxis post-transplant, routinely including posaconazole at our institution. These…
2022 American Transplant Congress
Effect Of The SRTR COVID-19 3-month Carve-out On Program-specific Transplant Outcome Evaluations
J. Miller¹, G. R. Lyden¹, D. Zaun¹, B. Kasiske², R. Hirose³, A. Israni², J. Snyder¹
¹Scientific Registry of Transplant Recipients, Minneapolis, MN, ²Hennepin County Medical Center, Minneapolis, MN, ³University of California, San Francisco, San Francisco, CA
*Purpose: The SRTR January 2022 program evaluations (Jan 2022 program-specific reports [PSRs]) applied a COVID-19 carve-out where follow-up for transplants performed before March 13, 2020,…
2022 American Transplant Congress
BK Polyomavirus Infection is Not Associated with a Meaningful Increase in Donor-Derived Cell-Free DNA
J. Fisher¹, K. Vieira¹, R. Burke², R. Gohh¹, R. Rogers¹
¹Warren Alpert Medical School of Brown University, Providence, RI, ²CareDx, Brisbane, CA
*Purpose: Donor-derived cell-free DNA (dd-cfDNA) is a non-invasive measure of early allograft injury that has been clinically validated as a surveillance tool to detect antibody…